This is the story of an older adult patient who had struggled for several years with chronic gastrointestinal inflammation and lower abdominal discomfort, driven by long-standing Ulcerative Colitis. This ongoing condition had severely affected her quality of life, daily comfort, appetite, and general energy levels the persistent abdominal pain and recurrent disease flare-ups made maintaining adequate nutrition and daily physical wellbeing increasingly difficult.

Despite her complex medical history, the patient stayed proactive in seeking care to manage her health and restore her vitality. She came to the clinic looking for supportive regenerative options to help calm chronic systemic inflammation, improve gut environment stability, and enhance her overall quality of life.

Where the Journey Began

The patient described an approximate 7-year history of chronic gastrointestinal symptoms, including persistent abdominal discomfort, loss of appetite, and altered bowel habits. Her medical records confirmed a known history of Ulcerative Colitis / Crohn’s disease, with periodic severe flare-ups including one major flare-up that required acute hospitalization. Diagnostic workups, including a colonoscopy, confirmed significant ulcerative inflammatory changes along the intestinal tract.

Her broader medical history also includes a separate hospitalization for a renal abscess, which was managed medically. Over the years, conventional conservative management and pharmaceutical interventions provided only temporary stabilization during acute exacerbations, without halting the condition’s long-term progression. Given the recurring impact on her energy, nutritional status, and daily functioning, she chose to explore an integrative approach that included supportive cell-based care.

What the Medical Workup Showed

An abdominal CT scan and laboratory evaluations revealed a combination of structural and systemic findings across several organ systems. Within the gastrointestinal tract, an irregular mass was identified in the lower right abdomen near the cecum, causing mild compression on adjacent small bowel loops, alongside a benign fatty lesion near the ileocecal valve and scattered non-inflamed diverticula in the lower colon. Evaluation of the liver, bile ducts, and spleen showed mild enlargement of specific liver lobes suspicious for early cirrhotic changes, mild bile duct dilatation, and marked splenic atrophy. The kidneys and pelvic organs showed multiple small fluid-filled cysts on both sides, along with two uterine fibroids. Normal kidney function markers confirmed the imaging contrast agent was cleared safely.

Taken together, these findings pointed to a complex picture rather than a single isolated problem chronic autoimmune bowel inflammation, impaired mucosal barrier integrity, localized soft-tissue compression, and systemic inflammatory strain all playing a part. This gave the care team a clear clinical rationale for considering cellular signalling therapy to help regulate immune balance, ease the overall inflammatory burden, and support tissue recovery.

Understanding Cell Therapy for This Condition

Cell Therapy using umbilical cord-derived cells is widely studied in regenerative gastroenterology for its capacity to release paracrine factors including anti-inflammatory cytokines, growth factors, and extracellular vesicles that may help modulate immune responses and support tissue repair.

For chronic autoimmune gastrointestinal conditions such as Ulcerative Colitis, Cell Therapy is not presented as a cure, and it cannot physically remove structural masses or lesions. It is offered as a supportive intervention intended to help regulate the biological environment within inflamed intestinal tissue. Key proposed mechanisms include:

• Modulating Intestinal Inflammation: helping downregulate excessive pro-inflammatory cytokine pathways driving mucosal breakdown.

• Supporting Immune System Balance: helping regulate immune cell activity to reduce autoimmune reactivity against gut tissue.

• Promoting Mucosal Microenvironment Healing: supporting paracrine signalling that encourages epithelial tissue repair and intestinal barrier recovery.

• Lowering Systemic Inflammatory Burden: providing systemic anti-inflammatory signalling that may benefit multi-organ health, which was particularly relevant given her co-existing findings.

After a thorough clinical consultation including a clear discussion of the CT findings and the presence of the lower-right-abdominal mass — the patient gave her informed consent to proceed with an individualized Cell Therapy programme integrated with IV nutrient support.

The Care Plan

Phase 1: Initial Cellular Support

The patient began her first phase of cellular care to address chronic systemic inflammation and gut mucosal stress, receiving intravenous Cell Therapy. This initial protocol was designed to provide broad immunomodulatory support, help reduce systemic inflammatory cytokines, and stabilise her baseline gut function.

Phase 2: Metabolic and Recovery Support

She next received integrative metabolic support a vitamin IV infusion combined with NAD+ to support recovery and cellular energy. During this period she was also closely monitored and managed through an intercurrent renal abscess hospitalisation, to ensure overall systemic stability before continuing with further cell therapy.

Phase 3: Reinforcement Protocol

Following re-evaluation and a further, detailed informed-consent discussion about her abdominal CT findings, the patient underwent an additional systemic Cell Therapy course, along with a supportive vitamin IV infusion. This phase aimed to reinforce immunomodulation, support ongoing gastrointestinal lining recovery, and assist her overall physical stamina.

What the Patient Noticed

After her treatment courses, the patient reported steady, meaningful improvements in her overall quality of life and daily comfort:

• Reduction in Abdominal Discomfort: a significant decrease in chronic lower abdominal pain and cramping episodes.

• Improved Appetite & Digestion: a gradual recovery of appetite and better tolerance of daily meals.

• Stabilised Energy Levels: noticeably better daily vitality and less systemic fatigue following her NAD+ and cell therapy infusions.

• Enhanced Wellbeing: greater confidence going about daily activities without constant concern over gastrointestinal distress.

Note: these are individual, self-reported observations. Clinical responses to regenerative therapies vary between individuals, depending on overall health, underlying disease complexity, and adherence to supportive care.

The Care Team’s Reflection

From a clinical standpoint, managing a chronic gastrointestinal condition like Ulcerative Colitis calls for a holistic, multi-dimensional assessment that goes beyond surface symptoms. In this case, the patient presented with meaningful structural and mucosal inflammation alongside co-existing findings such as the lower-right-abdominal mass, hepatic changes, and a history of renal infection.

Key takeaways from this case include:

• Multifactorial Assessment: autoimmune gut pain involves complex interactions between mucosal barrier breakdown, immune dysregulation, and systemic cytokine signalling.

• Careful Risk Mitigation & Consent: incidental structural findings, such as abdominal masses, need to be thoroughly evaluated and discussed transparently with the patient before any cell therapy is considered.

• Comprehensive Supportive Protocols: combining Cell Therapy with targeted metabolic support, such as NAD+ and micronutrient IVs, can support overall cellular resilience and recovery.

• Realistic Expectations: Cell Therapy is an integrative support tool intended to promote inflammatory balance and mucosal healing it is not an immediate cure or a substitute for surgery when one is needed.

Looking Back

This story reflects an individualised, regenerative care approach for an older adult patient managing chronic Ulcerative Colitis alongside a number of other medical considerations. Through structured phases of intravenous Cell Therapy, NAD+, and targeted IV vitamin support, she experienced noticeable improvements in abdominal comfort, appetite, energy, and overall quality of life.

Her case underlines the importance of careful diagnostic evaluation, open communication about risks and benefits, and a balanced clinical approach. Delivered responsibly, with patient safety and functional outcomes as the priority, systemic Cell Therapy can offer a valuable supportive option within a broader, long-term care plan.